Amphastar Pharmaceuticals (AMPH) Total Non-Current Liabilities (2014 - 2026)

Amphastar Pharmaceuticals has reported Total Non-Current Liabilities for 13 years, with the latest figure at $946.2 million in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 13.99% year-over-year to $946.2 million in Q2 2026; TTM through Jun 2026 was $946.2 million, a 13.99% increase from a year earlier, with the FY2025 full-year figure at $810.5 million, down 1.66% from the prior year.
• Total Non-Current Liabilities was $946.2 million for Q2 2026 at Amphastar Pharmaceuticals, up from $845.4 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $946.2 million in Q2 2026, with the low at $198.8 million in Q4 2022.
• Average Total Non-Current Liabilities over 5 years is $666.8 million, with a median of $817.4 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities surged 350.37% in 2023, then dropped 15.35% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $198.8 million in 2022, then soared by 328.03% to $850.8 million in 2023, then declined by 3.12% to $824.2 million in 2024, then dropped by 1.66% to $810.5 million in 2025, then grew by 16.74% to $946.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $946.2 million (Q2 2026), $845.4 million (Q1 2026), and $810.5 million (Q4 2025), per Business Quant data.